Search research articles
Contact Us
Filters
Showing results (191-200 of 214) with videos related to
Page
of 22
Sort By:
Oncology
|
November 17, 2011
Combination therapy for renal cell cancer: what are possible options?
Napoleon Santos, Justin B Wenger, Pamela Havre, et al.
Cancer Chemotherapy and Pharmacology
|
March 28, 2001
Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion
J L Grem, M Quinn, A S Ismail, et al.
Cancer Chemotherapy and Pharmacology
|
October 11, 2001
A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients
R R Thomas, W Dahut, N Harold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 2019
Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10
Jame Abraham, Albert J Montero, Rachel C Jankowitz, et al.
JCO Precision Oncology
|
December 3, 2024
Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms
Thomas J George, Ji-Hyun Lee, David L DeRemer, et al.
Cancer Chemotherapy and Pharmacology
|
August 9, 2025
NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated
Tanner J Freeman, Thomas J George, Samuel A Jacobs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 5, 2024
Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer
Lujia Chen, Ying Wang, Chunhui Cai, et al.
Breast Cancer Research : BCR
|
April 22, 2024
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer
Samuel A Jacobs, Ying Wang, Jame Abraham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2020
Neratinib-Plus-Cetuximab in Quadruple-WT (<i>KRAS, NRAS, BRAF, PIK3CA</i>) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study
Samuel A Jacobs, James J Lee, Thomas J George, et al.
Archives of Pathology & Laboratory Medicine
|
February 7, 2017
Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology
Antonia R Sepulveda, Stanley R Hamilton, Carmen J Allegra, et al.
Page
of 22
Search research articles
Search
Showing results (191-200 of 214) with videos related to
Sort By:
Page
of 22
Oncology
|
November 17, 2011
Combination therapy for renal cell cancer: what are possible options?
Napoleon Santos, Justin B Wenger, Pamela Havre, et al.
Cancer Chemotherapy and Pharmacology
|
March 28, 2001
Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion
J L Grem, M Quinn, A S Ismail, et al.
Cancer Chemotherapy and Pharmacology
|
October 11, 2001
A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients
R R Thomas, W Dahut, N Harold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 2019
Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10
Jame Abraham, Albert J Montero, Rachel C Jankowitz, et al.
JCO Precision Oncology
|
December 3, 2024
Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms
Thomas J George, Ji-Hyun Lee, David L DeRemer, et al.
Cancer Chemotherapy and Pharmacology
|
August 9, 2025
NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated
Tanner J Freeman, Thomas J George, Samuel A Jacobs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 5, 2024
Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer
Lujia Chen, Ying Wang, Chunhui Cai, et al.
Breast Cancer Research : BCR
|
April 22, 2024
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer
Samuel A Jacobs, Ying Wang, Jame Abraham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2020
Neratinib-Plus-Cetuximab in Quadruple-WT (<i>KRAS, NRAS, BRAF, PIK3CA</i>) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study
Samuel A Jacobs, James J Lee, Thomas J George, et al.
Archives of Pathology & Laboratory Medicine
|
February 7, 2017
Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology
Antonia R Sepulveda, Stanley R Hamilton, Carmen J Allegra, et al.
Page
of 22